Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Gastrointestinal Cancer
  •  Endoscopy Methods
  •  Surgical Oncology
  •  Chemoprevention
  •  Pancreatic Cancer
  •  Central Nervous System Tumors
  •  Neoadjuvant Therapy
  •  Urological Cancers

Abstract

Citation: Clin Oncol. 2016;1(1):1073.DOI: 10.25107/2474-1663.1073

Sunitinib in Special Situations in their Daily Practice

Molina Díaz A, Afonso Afonso FJ, Anido Herranz U, Lázaro Quintela M, Vázquez Estévez S, Santomé Couto L, Fernández Calvo O, Asensio Sampedro U and Antón Aparicio LM

Complejo Hospitalario Universitary de A Coruña, Spain
Complejo Hospitalario Universitary de Ferrol, Spain
Complejo Hospitalario Universitary de Santiago, Santiago de Compostela, Spain
Complejo Hospitalario Universitary de Vigo, Spain
Hospital Universitaio Lucus Augusti, Lugo, Spain
Hospital POVISA, Spain
Complejo Hospitalario Universitary de Orense, Spain
Departamento Médico de Pfizer Españ

*Correspondance to: Ant´┐Żn Aparicio LM 

 PDF  Full Text Review Article | Open Access

Abstract:

In the last decade, we have witnessed a change in the therapeutic management of patients with advanced kidney cancer. Systemic treatment of advanced Renal Cell Cancer (RCC) has been revolutionized by targeted therapy with drugs that block angiogenesis unfortunately; these studies are not always the reality of the practice of medical oncology at the inquiry reflected everyday and see how many subgroups of patients are not represented appropriately. Many patients with RCC do not meet inclusion criteria. For instance, more than 40% of patients with metastatic RCC are in special situations, i.e. elderly patients, bone metastases, hepatic impairment, type 1 and 2 diabetes, renal insufficiency and end-stage renal disease , haemodialysis , brain metastases, and unresectable surgery. These patients are poorly represented in trials. Little is known about the activity of targeted therapies, such of sunitinib, in these subsets of patients. It could be a benefit of sunitinib treatment for these patients, with good tolerance, by personalizing treatment in each situation. In this article, we review the use of sunitinib in these real practice patients and its specials situations.

Keywords:

Cite the Article:

Molina Díaz A, Afonso Afonso FJ, Anido Herranz U, Lázaro Quintela M, Vázquez Estévez S, Santomé Couto L, et al. Sunitinib in Special Situations in their Daily Practice. Clin Oncol. 2016; 1: 1073.

Search Our Journal

Journal Indexed In

Articles in PubMed

LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
NMR Metabolomics in Ionizing Radiation
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Bovine Milk Derived Exosomal - Curcumin Exhibiting Enhanced Stability, Solubility, and Cellular Bioavailability
 Abstract  PDF  Full Text
Outcome of Allogeneic Bone Marrow Transplantation for Acute Myeloid Leukemia Following Single Agent Induction with Hypomethylation
 PDF  Full Text
View More...